-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Gene Therapy To Target SLAMF7 For Multiple Myeloma in Multiple Myeloma (Kahler Disease)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Gene Therapy To Target SLAMF7 For Multiple Myeloma in Multiple Myeloma (Kahler Disease) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Gene Therapy To...
-
Product Insights
Plasma Cell Neoplasm – Drugs In Development, 2023
Global Markets Direct’s, ‘Plasma Cell Neoplasm - Drugs In Development, 2023’, provides an overview of the Plasma Cell Neoplasm pipeline landscape. The report provides comprehensive information on the therapeutics under development for Plasma Cell Neoplasm, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Company Profile
Hester Biosciences Ltd – Company Profile
Hester Biosciences Ltd (Hester Biosciences) is a distributor and manufacturer of animal vaccines and health products. The company's product portfolio includes Inactivated Vaccines, Live Vaccines, and animal and poultry healthcare products. It offers services including Mastitis control programmes for cattle and Seroprofiling for poultry flocks. The company markets its poultry health products under Betamix AP, Betamix P, AFLORIN-PL, CuRX, EFFIBOOST and EFFIGUT among other brand names. The company markets large animal health products under BETA4VET, HFM, HIFCR, Inomilk Gold, Inomilk,...
Add to Basket -
Product Insights
Acute Myelocytic Leukemia (AML) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
AML Pipeline Products Market Report Overview Acute myelocytic leukemia (AML), also known as acute myelogenous leukemia is a type of cancer that affects the blood and the bone marrow. Immature white blood cells accumulate in the bone marrow thus blocking the production of normal blood cells. These cells further enter the bloodstream and spread to the other parts of the body. Symptoms of AML include fatigue, fever, bleeding, breathing problems, and weight loss. The predisposing factors involved are exposed to...
-
Product Insights
Multiple Myeloma (Kahler Disease) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Multiple Myeloma Pipeline Products Market Report Overview Multiple myeloma is a type of cancer that is caused by malignant plasma cells that proliferate in the bone marrow and produce abnormally high amounts of a special protein. The exact cause of multiple myeloma is not clear. It mainly affects older adults. Symptoms include anemia, bleeding, nerve damage, skin lesions, bone tenderness or pain, and kidney failure. Treatment includes chemotherapy, radiation, immunosuppression, and surgery. The Multiple Myeloma Drugs in Development market research...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Gene Therapy to Target SLAMF7 for Multiple Myeloma
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry Gene Therapy to Target SLAMF7 for Multiple Myeloma Drug Details Gene therapy is under...
-
Product Insights
Epilepsy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Epilepsy is a neurological disorder characterized by the transmission of abnormal signals produced by a group of neurons in the brain which causes seizures. This leads to brief disruptions of the senses and short periods of unconsciousness or convulsions. Symptoms of epilepsy are repeated seizures, weakness, anxiety, loss of consciousness, and contraction or jerking of body muscles. The Epilepsy Drugs in Development market research report provides an overview of the Epilepsy pipeline landscape. The report provides comprehensive information on the...
-
Product Insights
Neonatal Seizures Global Clinical Trials Review, H1, 2018
GlobalData's clinical trial report, “Neonatal Seizures Global Clinical Trials Review, H1, 2018" provides an overview of Neonatal Seizures clinical trials scenario. This report provides top line data relating to the clinical trials on Neonatal Seizures. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Sector Analysis
PharmaPoint: Epilepsy – Global Drug Forecast and Market Analysis to 2026
Epilepsy is a brain disorder characterized by spontaneously occurring and recurrent seizures. Seizures result from abnormal electrical discharges in the brain and vary in their manifestations, from the brief staring spells that are characteristic of absence seizures, to full-body convulsions known as tonic-clonic seizure. Epilepsy can be considered a spectrum disorder due to its different causes, different seizure types, and different disease severities. There are several anti-epileptic drugs (AEDs) on the market, with an older generation fully genericized across the...